BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Das D, Hong J, Chen SH, Wang G, Beigelman L, Seiwert SD, Buckman BO. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorg Med Chem 2011;19:4690-703. [PMID: 21798747 DOI: 10.1016/j.bmc.2011.06.079] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Barreca ML, Manfroni G, Leyssen P, Winquist J, Kaushik-Basu N, Paeshuyse J, Krishnan R, Iraci N, Sabatini S, Tabarrini O, Basu A, Danielson UH, Neyts J, Cecchetti V. Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. J Med Chem 2013;56:2270-82. [PMID: 23409936 DOI: 10.1021/jm301643a] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
2 Elfiky AA. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study. Med Chem 2019;15:130-7. [PMID: 30324891 DOI: 10.2174/1573406414666181015152511] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
3 Ezat AA, Elfiky AA, Elshemey WM, Saleh NA. Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study. Virusdisease 2019;30:207-13. [PMID: 31179358 DOI: 10.1007/s13337-019-00516-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
4 Elaziz MA, Moemen YS, Hassanien AE, Xiong S. Quantitative Structure-Activity Relationship Model for HCVNS5B inhibitors based on an Antlion Optimizer-Adaptive Neuro-Fuzzy Inference System. Sci Rep 2018;8:1506. [PMID: 29367667 DOI: 10.1038/s41598-017-19122-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
5 Elfiky AA, Ismail AM. Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor. Future Virology 2017;12:339-47. [DOI: 10.2217/fvl-2017-0027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
6 Paparin JL, Amador A, Badaroux E, Bot S, Caillet C, Convard T, Da Costa D, Dukhan D, Griffe L, Griffon JF, LaColla M, Leroy F, Liuzzi M, Giulia Loi A, McCarville J, Mascia V, Milhau J, Onidi L, Pierra C, Rahali R, Rosinosky E, Sais E, Seifer M, Surleraux D, Standring D, Dousson CB. Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor. Bioorg Med Chem Lett 2017;27:2634-40. [PMID: 28416131 DOI: 10.1016/j.bmcl.2017.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Pourbasheer E, Aalizadeh R, Shokouhi Tabar S, Ganjali MR, Norouzi P, Shadmanesh J. 2D and 3D Quantitative Structure–Activity Relationship Study of Hepatitis C Virus NS5B Polymerase Inhibitors by Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis Methods. J Chem Inf Model 2014;54:2902-14. [DOI: 10.1021/ci500216c] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
8 Wei Y, Li J, Qing J, Huang M, Wu M, Gao F, Li D, Hong Z, Kong L, Huang W, Lin J. Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking. PLoS One 2016;11:e0148181. [PMID: 26845440 DOI: 10.1371/journal.pone.0148181] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
9 Ganta NM, Gedda G, Rathnakar B, Satyanarayana M, Yamajala B, Ahsan MJ, Jadav SS, Balaraju T. A review on HCV inhibitors: Significance of non-structural polyproteins. Eur J Med Chem 2019;164:576-601. [PMID: 30639895 DOI: 10.1016/j.ejmech.2018.12.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
10 Jin G, Lee J, Lee K. Chemical genetics-based development of small molecules targeting hepatitis C virus. Arch Pharm Res 2017;40:1021-36. [PMID: 28856597 DOI: 10.1007/s12272-017-0949-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Elfiky AA, Elshemey WM. IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study. Med Chem Res 2016;25:1005-8. [PMID: 32214769 DOI: 10.1007/s00044-016-1533-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
12 Gobis K, Foks H, Sławiński J, Augustynowicz-Kopeć E, Napiórkowska A. Synthesis and biological activity of novel 3-heteroaryl-2H-pyrido[4,3-e][1,2,4]thiadiazine and 3-heteroaryl-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxides. Monatsh Chem 2013;144:1197-203. [PMID: 26166884 DOI: 10.1007/s00706-013-0988-5] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
13 Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol 2016;88:2044-51. [PMID: 27604059 DOI: 10.1002/jmv.24678] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]
14 Nazari M, Nematpour M, Rezaee E, Jahani M, Tabatabai SA. A new route for the synthesis of functionalized benzothiadiazine 1,1-dioxide derivatives via intramolecular C–H activation reactions of N , N ′, N ′′-trisubstituted guanidines and benzenesulfonylchloride. Journal of Sulfur Chemistry 2018;39:646-55. [DOI: 10.1080/17415993.2018.1499743] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Elfiky AA. Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase. Future Virology 2017;12:721-8. [DOI: 10.2217/fvl-2017-0081] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
16 Byrappa S, Harsha Raj M, Kungyal T, Kudva N NU, Salimath BP, Lokanatha Rai KM. Synthesis and biological evaluation of novel isoxazolines linked via piperazine to 2- benzoisothiazoles as potent apoptotic agents. Eur J Med Chem 2017;126:218-24. [PMID: 27821324 DOI: 10.1016/j.ejmech.2016.09.094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
17 Wang M, Zhong M, Yan A, Li L, Yu C. Quantitative structure and bioactivity relationship study on HCV NS5B polymerase inhibitors. SAR QSAR Environ Res 2014;25:1-15. [PMID: 24283437 DOI: 10.1080/1062936X.2013.820790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Hu Z, Martí J, Lu H. Structure of benzothiadiazine at zwitterionic phospholipid cell membranes. J Chem Phys 2021;155:154303. [PMID: 34686044 DOI: 10.1063/5.0065163] [Reference Citation Analysis]
19 Wang M, Wang K, Yan A, Yu C. Classification of HCV NS5B polymerase inhibitors using support vector machine. Int J Mol Sci. 2012;13:4033-4047. [PMID: 22605964 DOI: 10.3390/ijms13044033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
20 Elfiky AA, Elshemey WM, Gawad WA, Desoky OS. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J 2013;32:75-80. [PMID: 23322006 DOI: 10.1007/s10930-013-9462-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]